Objective: The paper systematically analyzes the four batches (including three batches of national procurement and a batch of follow-up procurement) of national high-value medical consumables centralized volume-based procurement rules and selected results, in order to reflect the trend of China's high-value medical consumables centralized volume-based procurement. Methods: By analyzing the four batches of procurement documents, the procurement rules are compared from five aspects, i.e. the proportion of intended procurement, grouping rules, quotation rules, selection rules, and volume allocation rules. Also we analyze the selected results from two aspects of selected price and selected enterprises and summarize the trend of centralized volume-based procurement of high-value medical consumables in China. Results: According to comparison of the rules, the proportion of intended procurement is increasing, grouping rules reflect homogeneous competition in the same group, the price composition becomes more detailed, selection rules tend to stabilize the clinical supply, and volume allocation rules reflect quantity-price linkage. According to the selected results, the prices of selected drugs decrease to 80%, the difference of selected price gradually narrows to less than 1.5 times, the domestic share of national varieties steadily increases, domestic substitution further strengthens, the selected rate of enterprises gradually increases and stabilizes at 90%, the leading enterprises are selected and the industry concentration further increases. Conclusion: Combining the analysis above with the current situation of the procurement, the paper summarizes the seven trends of high-value medical consumables centralized volume-based procurement in China, namely, procurement rules design is more focused on the protection of market stability, procurement scope continues to expand and almost all varieties can be selected, we form a new pattern of pharmaceutical centralized volume-based procurement with collaborative promotion, a number of initiatives support the procurement to move towards a new journey of comprehensive price management, varieties focus on low localization rate areas and domestic replacement process accelerated, centralized procurement promotes enterprise innovation and realizes the high-quality development of pharmaceutical industry, centralized procurement synergy "medical insurance-medical treatment-drugs linkage" to promote the development of pharmaceutical industry.